Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Global surge in energy innovation as TERA-Award draws record-breaking 785 entries 25-04-2025, 14:32

Impact Professionals Finds Success With Its 1-02-2023, 05:38